From September 6 to 7 2024, the Porton Wecare Program accompanied the families of four Chongqing DMD patients to Shanghai to participate in the 13th China Rare Disease Summit 2024.
The summit, co-sponsored by the Chinese Organization for Rare Disorders …
As a proud gold sponsor of the Pharma Crystallization Summit 2024 (PCS 2024), the Crystallization Team at Porton, with locations in New Jersey (USA) and Shanghai (China), offers expert services in polymorph discovery and selection, crystallization process development, particle …
CPhI Europe (October 8-10) in Milan, Italy, stands as a worldwide event in the pharmaceutical industry, bringing together key players, thought leaders, and businesses from across the globe. At this year’s exhibition, Porton will showcase its end-to-end global CDMO service …
AAPS PharmSci 360 is the annual meeting of the American Association of Pharmaceutical Scientists (AAPS), a leading professional organization for pharmaceutical scientists. The event focuses on advancing fundamental knowledge and scientific progress in the pharmaceutical sciences. Upcoming PharmSci 360 conferences …
CPhI Worldwide is the largest pharmaceutical exhibition, bringing together the global pharma community to network, source cost-effective solutions, and stay up-to-date on industry trends. It is held annually and organized by Informa Markets, a leading events company. The event has …
The Pharma Crystallization Summit (PCS) 2024 is an annual event that brings together developers of new medicines with crystallization challenges and the crystallization experts who can help address them. The summit aims to improve the effectiveness of addressing crystallization issues …
ChemOutsourcing is the largest USA-based API and Pharmaceutical Ingredients Sept show attracting annually 700-800 customers, project and executive management and business development personnel from the pharmaceutical, biotech, chemical, and chemistry services industries from 30 countries. The high level event focuses …
In the pharmaceutical industry, the development of crystallization processes—including for APIs and intermediates, as well as early-stage formulation development—plays a crucial role in the drug development and manufacturing process. Different crystal forms, sizes, and habits can significantly influence the physicochemical …
On July 16, 2024, Porton Pharma Solutions Ltd. (hereinafter referred to as “Porton”, “the company”, “We”) announced that its Chongqing Changshou Site (CQ2) had undergone a cGMP (current Good Manufacturing Practice) on-site inspection by the U.S. Food and Drug Administration …
Recently, the crystallization team at Porton and Genentech, Inc. jointly published a paper titled “Phase Transitions Involving Channel Hydrates of a New Pharmaceutical Compound” in 《Pharmaceutical Research》, the official journal of the American Association of Pharmaceutical Scientists. This journal focuses …
On June 14, 2024, Dr. Francesco Fontana (R&D Director), Dr. Dario Telese (Lead Chemist), and Dr. Lucija Ptiček (Synthesis Laboratory Specialist) from the Porton Slovenian site presented a lecture on the Master PRO-API program of the University of Perugia. The …
June 2024 — Porton J-STAR today announced that Enabling Technologies Consortium (ETC) has awarded a two-year contract to J-STAR to collaborate on “Co-processing Platform Technology.”
The primary goal of co-processing is to improve the reliability and efficiency of drug product …
